hrp0084p2-265 | Diabetes | ESPE2015

Importance of Thrombocyte Volume Parameters in Type 1 Diabetes Mellitus Patients with and without Clinical Findings of Diabetic Ketoacidosis

Vuralli Dogus , Aksoy Hatice Tatar , Yilmaz Arzu , Engiz Ozlem , Dallar Yildiz Bilge

Background: Thrombocyte volume parameters such as mean thrombocyte volume (MPV) and PDW (thrombocyte distribution volume) are parameters used in evaluation of thrombocyte size which have hemostatic importance. The increased thrombocyte volume is a marker of thrombocyte activation. The thrombocyte activity is important in pathophysiology of diseases with a tendency of thrombosis and inflammation. In adult studies it has been reported that MPV increases in thrombotic diseases su...

hrp0084p3-704 | Diabetes | ESPE2015

Diabetic Ketoacidosis Treatment: Experience from a Paediatric Tertiary Centre (2004–2014)

Serra-Caetano Joana , Gata Lia , Dinis Alexandra , Cardoso Rita , Dinis Isabel , Mirante Alice

Background: Diabetic ketoacidosis (DKA) is a medical emergency. The most physiologic fluid/electrolytes replacement rates and insulin dosis are still controversial.Objective and hypotheses: To evaluate the effectiveness and security of DKA treatment. Our protocol consists of 2 h’ rehydration with 0.9% sodium chloride (NaCl), followed by insulin infusion (0.1 U/kg per h) associated to 0.45% NaCl with 5% glucose. Potassium is replaced with monophospha...

hrp0094p2-390 | Pituitary, neuroendocrinology and puberty | ESPE2021

A case of partially Empty Sella with hypopituitarism in a child

Pratap Rajat , Mason Leah , Basu Supriyo ,

Introduction: Empty Sella (ES) is a radiological finding which is due to herniation of subarachnoid space into sella turcica. It’s partial, when <50% space is filled with cerebrospinal fluid (CSF) and complete, when CSF fills >50% with pituitary gland flattened to <=2mm. Actual occurrence is debatable and often noted incidentally during magnetic resonance imaging (MRI). However, it can cause pituitary hormone (PH) dysfunctions, most commonly g...

hrp0097p1-439 | Diabetes and Insulin | ESPE2023

Determinants And Characteristics Of Insulin Dose Requirements In Children And Adolescent With New-Onset Type 1 Diabetes: Insights From The INSENODIAB Study

Beckers Maude , Lysy Philippe , Polle Olivier , Bernard Noémie , Gallo Paola

Aims: In children with new-onset type 1 diabetes mellitus (T1D), insulin dose regimens vary substantially. According to current ISPAD recommendations, the initial total daily dose (TDD) should range from 0.7 to 1.0 IU/kg BW/day. Adjusting TDD to achieve normal blood glucose concentration can take several days. The primary objectives of our INSENODIAB (INsulin SEnsitivity in New Onset type 1 DIABetes) study were to assess how patient characteristics influence i...

hrp0097p2-240 | Diabetes and Insulin | ESPE2023

Fulminant Type 1 Diabetes Case With Positive Diabetes-Associated Antibodies

Hürmüzlü Közler Selen , Koçyiğit Esra , Sarı Ersöz Hilal , Gürpınar Gözde , Kilci Fatih , Jones Jeremy , Mine Çizmecioğlu Jones Filiz

Introduction: Fulminant type 1 diabetes (FT1D) occurs because of a sudden and almost total destruction of pancreatic β-cells, triggered by a viral infection. FT1DM may cause diabetic ketoacidosis (DKA) and even sudden death. Thus prompt diagnosis is vital.Case Report: Antibiotic treatment was started for a 4-year-old female patient because of a fever and cough. On the second day of treatment, she was admitted with r...

hrp0097p1-311 | Growth and Syndromes | ESPE2023

Management of rhGH treatment in children with CKD in current clinical practice: a multicentric study

Labey Séverine , Hogan Julien , Salomon Rémi , Ulinski Tim , Boizeau Priscilla , Carel Jean-Claude , Simon Dominique

Introduction: Growth retardation < –2 SDS is frequently observed in children with chronic kidney disease (CKD) and is a marker of severity of CKD. Recombinant human growth hormone (rhGH) treatment has been approved since 1995 in CKD patients. The aim of this study was to describe the growth outcomes and treatment patterns in children with congenital CKD.Methods: Patients were recruited from transplantation recor...

hrp0089p2-p195 | Fetal, Neonatal Endocrinology and Metabolism P2 | ESPE2018

The Benefit of Universal Neonatal Screening for Hypoglycemia

Nicolas Georges , chaaban Riham , faddous-Khalifeh Marie-Claude , Souaiby Juliana , Salemeh Yara

Introduction: Hypoglycemia is a common problem in neonatal period associated with adverse neurological outcome and brain injury if treatment was not provided. AAP and PES recommended screening for hypoglycemia only in newborns with risk factors but many others neonates may present episodes of asymptomatic hypoglycemia without any known risk factor.Objectives: To assess the incidence of hypoglycemia in healthy full term neonates without any risk factors i...

hrp0084p2-251 | Diabetes | ESPE2015

Sick Day Rule: Survey of Parents of Children with Type 1 Diabetes (Experience and Knowledge)

Agwu Juliana Chizomam , Ng S May , Drew J , Edge J , Kershaw M , Wright N , Gardner C

Background: Inappropriate management of illness/stress, accidental or deliberate insulin omission are some of the causes of Diabetes ketoacidosis (DKA) in patients with established diabetes. During illness, patients with type 1 diabetes are advised to monitor for hyperglycaemia and ketosis, maintain fluid intake and if required, to administer supplemental insulin. Previous studies have confirmed that comprehensive diabetes self- management education (DSME) programs on manageme...

hrp0094p2-235 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

A Selective Nonpeptide Somatostatin Receptor 5 (SST5) Agonist Effectively Decreases Insulin Secretion in a KATPHI Mouse Model and in Human HI Islets

Juliana Christine , Chai Jinghua , Arroyo Pablo , Rico-Bautista Elizabeth , Betz Stephen , De Leon Diva ,

Inactivating mutations of ß-cell KATP channels cause the most common and severe form of congenital hyperinsulinism (HI), a ß-cell disorder that results in dysregulated insulin secretion and persistent hypoglycemia. Children with KATPHI are typically unresponsive to diazoxide, the only FDA-approved drug for HI. Octreotide, an SST2-selective agonist peptide that inhibits insulin secretion, is used as second line therapy, but poor efficacy and SST2...

hrp0094p1-48 | Sex Endocrinology and Gonads A | ESPE2021

Gonadal Outcome in 17beta-HSD deficiency and 5alpha-reductase deficiency

Boogers Lidewij S , Bruggenwirth Hennie T , van Bever Yolande , Hersmus Remko , Bryce Jilian , Ahmed S Faisal , Lucas-Herald Angela K , Baronio Federico , Cools Martine , Ellaithi Mona , Globa Evgenia , Guran Tulay , Tosun Busra Gurpinar , Hiort Olaf , Holterhus Paul-Martin , McElreavey Ken , Niedziela Marek , Stancampiano Marianna Rita , Wolffenbuttel Katja P , Oosterhuis J Wolter , Looijenga Leendert HJ , Hannema Sabine E ,

Introduction: 5α-reductase type 2 deficiency (5α--RD) and 17β-HSD type 3 deficiency (17β-HSDD) are rare differences/disorders of sex development (DSD) in which impairment of steroidogenic enzymes causes undervirilisation in patients with a 46,XY genotype. We aim to enlarge the limited knowledge on long-term gonadal function and gonadal pathology in these conditions.Methods: Data on phenotype, laborato...